ImmuCell (ICCC)
(Delayed Data from NSDQ)
$3.60 USD
-0.03 (-0.83%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.53 -0.07 (-1.94%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for ImmuCell Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 17 | 19 | 19 | 15 | 14 |
Cost Of Goods | 14 | 11 | 11 | 8 | 7 |
Gross Profit | 4 | 8 | 9 | 7 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 10 | 10 | 8 | 8 | 8 |
Income After Depreciation & Amortization | -6 | -2 | 0 | -1 | -1 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -6 | -2 | 0 | -1 | -1 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -6 | -2 | 0 | -1 | -1 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -6 | -2 | 0 | -1 | -1 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -3 | 0 | 3 | 1 | 1 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 2 | 2 | 2 |
Income After Depreciation & Amortization | -6 | -2 | 0 | -1 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 7.75 | 7.75 | 7.59 | 7.21 | 6.82 |
Diluted EPS Before Non-Recurring Items | -0.75 | -0.32 | -0.01 | -0.14 | -0.19 |
Diluted Net EPS (GAAP) | -0.75 | -0.32 | -0.01 | -0.14 | -0.19 |
Fiscal Year end for ImmuCell Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 5.47 | 7.26 | 5.10 | 5.40 | 3.53 |
Cost Of Goods | 4.24 | 4.96 | 3.84 | 4.13 | 2.49 |
Gross Profit | 1.23 | 2.30 | 1.26 | 1.27 | 1.04 |
SG&A, R&D, and Dept/Amort Expenses | 2.62 | 2.59 | 2.26 | 2.45 | 2.35 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.39 | -0.29 | -1.00 | -1.18 | -1.31 |
Non-Operating Income | -0.14 | -0.14 | -0.13 | 0.24 | -0.07 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -1.53 | -0.44 | -1.14 | -0.94 | -1.38 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.53 | -0.44 | -1.14 | -0.94 | -1.38 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.53 | -0.44 | -1.14 | -0.94 | -1.38 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 7.81 | 7.75 | 7.75 | 7.75 | 7.75 |
Diluted EPS Before Non-Recurring Items | -0.20 | -0.06 | -0.15 | -0.12 | -0.18 |
Diluted Net EPS (GAAP) | -0.20 | -0.06 | -0.15 | -0.12 | -0.18 |